Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease

Exclusion Criteria

• •Participants with other significant disease that may interfere with the interpretation of study data (e.g., other neuromuscular diseases) and/or ability to complete the tests, in the opinion of the Investigator.
• •Participants with laboratory test result abnormalities at screening considered clinically significant by the Investigator.
• •Participants who have received treatment with another IMP within 30 days (or 5 half-lives of the medication, whichever is longer) prior to day 1.
• •Participants with history of poor compliance with relevant therapy in the opinion of the Investigator.
• •Female participants who plan to become pregnant during the study or are currently pregnant or breastfeeding.